NeuBase Therapeutics – Consensus Indicates Potential 92.5% Upside

Broker Ratings

NeuBase Therapeutics with ticker code (NBSE) now have 6 analysts covering the stock with the consensus suggesting a rating of ‘Strong_Buy’. The target price ranges between 18 and 13 calculating the mean target price we have 15.67. Given that the stocks previous close was at 8.14 this indicates there is a potential upside of 92.5%. The 50 day MA is 8.06 and the 200 moving average now moves to 8.32. The company has a market capitalisation of $180m. You can visit the company’s website by visiting: http://www.neubasetherapeutics.com

NeuBase Therapeutics, a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company’s proprietary peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington’s disease (HD) and myotonic dystrophy, as well as other genetic disorders. Its lead programs include NT0100, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the HD messenger ribonucleic acid (mRNA); and NT0200, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the myotonic dystrophy type 1 disease mRNA. NeuBase Therapeutics is headquartered in Pittsburgh, Pennsylvania.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on whatsapp
WhatsApp